Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of opicapone on nocturnal hypokinesia in patients with Parkinson’s disease
KCT0010294Phase 4Completed
- Sponsor
- Samil Pharmaceutical Co., Ltd.
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of opicapone in Parkinson's disease (PD), sponsored by Samil Pharmaceutical Co., Ltd.. Started Jun 2023; status: completed.
02
Drugs
opicapone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on KCT0010294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0010294.